Qube Research & Technologies LTD Denali Therapeutics Inc. Transaction History

Qube Research & Technologies LTD

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$15.83 - $23.35 $2.11 Million - $3.12 Million	-133,513 Reduced 77.96%	37,749 $774,000
Q4 2023 Feb 13, 2024	BUY	$16.2 - $23.18 $2.55 Million - $3.66 Million	157,709 Added 1163.65%	171,262 $3.68 Million
Q3 2023 Nov 13, 2023	BUY	$20.63 - $30.17 $279,598 - $408,894	13,553 New	13,553 $279,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.